ClinicalTrials.gg
Not yet recruitingNCT07768917Updated Aug 17, 2026

Training on Systemic and Organ Spec. PM in PC

An interventional study of Exercise in Prostate Cancer, sponsored by Massachusetts General Hospital. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Prostatic Neoplasms by Massachusetts General Hospital — 4 open to participants now, 5 under way, none of them phase 3. Prostatic Neoplasms · Massachusetts General Hospital.

Planned enrollment
14th of 20
20 · median 35
Started
2026
the only one that year
No phase
7 of 32
1 open now
Registered
32nd of 32
by date

Among the 32 studies in Prostatic Neoplasms by Massachusetts General Hospital, this one is the 14th largest by planned enrollment of the 20 interventional ones that give a count, is the only one that started in 2026, is one of 7 with no phase, and was the 32nd registered.

Prostatic Neoplasms

7,055 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

4 of the 32 studies in Prostatic Neoplasms by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Prostatic Neoplasms by Massachusetts General Hospital, or all of them as a file.
02

Study summary

This research is being done to assess the impact of a supervised and structured strength and conditioning program on cardiac remodeling in participants with prostate cancer undergoing treatment with external beam radiation therapy and at least 6 months of Gonadotropin-releasing hormone (GnRH) therapy.

Read the detailed description

This study is designed to determine the impact of a strength and conditioning program on cardiac remodeling in participants with prostate cancer undergoing treatment with external beam radiation therapy and at least 6 months of Gonadotropin-releasing hormone (GnRH) therapy. In this study the participants will complete an exercise program that includes structured strength and conditioning programs which may include weightlifting, running, cycling, and stretching. During the research study participants will have data collected and blood samples taken which will be used to evaluate the prevention and reduction of potential harms induced by prostate cancer treatment. Participants will be in this research for 7 months which includes 6-months of the exercise intervention along with 1-month post-intervention activities. It is expected that about 20 people will take part in this research study.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Prescribed Physical Training
  • Exercise Program
  • Systemic and Organ Specific Prognostic Markers in Prostate Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have or cytologically confirmed adenocarcinoma of the prostate
  • Have not received GnRH agonist or antagonist within the last 12 months
  • Planned for initiation of a GnRH agonist or antagonist or bilateral orchiectomy with an intended treatment duration of ≥ 6 months
  • Planned for initiation of radiation therapy to the prostate.
  • performance status of 0 or 1
  • Ability to understand and the willingness to sign a written document
  • Baseline serum total testosterone level > 230 ng/dL (the accepted threshold for testosterone supplementation)
  • Speak English ->18 years of age

Exclusion criteria

Exclusion Criteria:

  • Has a known medical condition that makes the subject unable to participate in exercise testing (e.g. unrevascularized coronary artery disease, moderate/severe osteoarthritis, prior stroke, or other conditions)
  • Receiving or planned to receive other cancer therapy not included in Eligibility Criterion 3.1.3 (other than an antiandrogen during the first month of therapy)
  • The following populations will not be considered for inclusion on this trial.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Other
    Exercise Program

    Participants will undergo a 6-month exercise program.

    Other: Exercise

Interventions

  • OtherExercise

    Supervised and structured strength and conditioning program

06

What researchers measure

Primary outcomes

  1. Left Ventricular Ejection Fraction

    Left ventricular ejection fraction (%) as measured by echocardiogram

    Time frame: At the start of the exercise program for up to 6 month after exercise program.

  2. Left Ventricular Mass

    Left ventricular mass (g) as measured by echocardiogram

    Time frame: Time Frame: At the start of the exercise program for up to 6 month after exercise program.

  3. Left Ventricular Mass Index (g/m2)

    Left ventricular mass index (g/m2) as measured by echocardiogram

    Time frame: Time Frame: At the start of the exercise program for up to 6 month after exercise program.

  4. Posterior cardiac wall thickness (mm)

    Posterior cardiac wall thickness (mm) as measured by echocardiogram.

    Time frame: Time Frame: At the start of the exercise program for up to 6 month after exercise program.

  5. Relative cardiac wall thickness (ratio)

    Relative cardiac wall thickness (ratio) as measured by echocardiogram

    Time frame: Time Frame: At the start of the exercise program for up to 6 month after exercise program.

  6. Left ventricular end-diastolic and end-systolic dimension (mm)

    Left ventricular end-diastolic and end-systolic dimension (mm) as measured by echocardiogram.

    Time frame: Time Frame: At the start of the exercise program for up to 6 month after exercise program.

  7. Cardiac output (L/min)

    Cardiac output (L/min) as measured by echocardiogram.

    Time frame: Time Frame: At the start of the exercise program for up to 6 month after exercise program.

  8. Heart rate (bpm)

    Heart rate (bpm) as measured by Cardiopulmonary Exercise Testing

    Time frame: Time Frame: At the start of the exercise program for up to 6 month after exercise program.

  9. Blood pressure, systolic and diastolic (mmHg)

    Blood pressure, systolic and diastolic (mmHg) as measured at Cardiopulmonary Exercise Testing

    Time frame: Time Frame: At the start of the exercise program for up to 6 month after exercise program.

  10. VO2max (mL/kg/min)

    VO2max (mL/kg/min) as measured on Cardiopulmonary Exercise Testing

    Time frame: Time Frame: At the start of the exercise program for up to 6 month after exercise program.

  11. C-reactive protein (mg/L)

    C-reactive protein (mg/L) measured by blood draw

    Time frame: Time Frame: At the start of the exercise program for up to 1 month after exercise program.

  12. Erythrocyte sedimentation rate (mm/hr)

    Erythrocyte sedimentation rate (mm/hr) measured by blood draw

    Time frame: Time Frame: At the start of the exercise program for up to 1 month after exercise program.

  13. Neutrophil lymphocyte ratio (ratio)

    Neutrophil lymphocyte ratio (ratio) as measured from blood draw values

    Time frame: Time Frame: At the start of the exercise program for up to 1 month after exercise program.

  14. Systemic immune-inflammation index (SII)

    Systemic immune-inflammation index (SII) as derived from blood draw values

    Time frame: Time Frame: At the start of the exercise program for up to 1 month after exercise program.

  15. Hand grip strength (kg)

    Hand grip strength (kg) measured by dynamometer

    Time frame: Time Frame: At the start of the exercise program for up to 1 month after exercise program.

  16. Timed up and go test (seconds)

    Timed up and go test (seconds) measured by stopwatch during exercise testing.

    Time frame: Time Frame: At the start of the exercise program for up to 1 month after exercise program.

  17. Fatigue and health related quality of life (SF-36 questionnaire)

    Fatigue and health related quality of life (SF-36 questionnaire) measured by standardized patient questionnaire.

    Time frame: Time Frame: At the start of the exercise program for up to 1 month after exercise program.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Request may be directed to Peter Lee, MD, PhD. The protocol and statistical analysis plan will be made available on ClinicalTrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data can be shared no earlier than 1 year following the date of publication

Access criteria: Contact the Partners Innovations team at http://www.partners.org/innovation

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jan 2027, 1 month later.

Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 1 month is below that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2026
First posted
Aug 17, 2026
StartEst.
Dec 10, 2026
Primary completionEst.
Jan 31, 2027
CompletionEst.
Mar 31, 2027
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07768917
Responsible party
Peter Lee (Principal Investigator, Massachusetts General Hospital) — Principal investigator
First posted
Aug 17, 2026
Start date
Dec 10, 2026 (estimated)
Primary completion
Jan 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Aug 17, 2026

Study contacts

Peter J. Lee, MD, PhD
Contact
plee22@mgh.harvard.edu
617-724-4000
Peter Lee, MD, PhD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion